PubRank

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Clinical Trial ID NCT01828099

PubWeight™ 21.37‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01828099

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
2 Novel ALK inhibitors in clinical use and development. J Hematol Oncol 2015 1.24
3 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
4 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
5 Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res 2015 1.07
6 Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014 1.05
7 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014 0.93
8 Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014 0.92
9 ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014 0.89
10 Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist 2016 0.87
11 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
12 Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol 2016 0.83
13 Recent advances in personalized lung cancer medicine. Per Med 2014 0.82
14 Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol 2015 0.80
15 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
16 Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther 2015 0.78
17 New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Ther Clin Risk Manag 2016 0.77
18 Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016 0.76
19 PROFILE 1014: lessons for the new era of lung cancer clinical research. Transl Lung Cancer Res 2015 0.76
20 Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016 0.75
21 Targeted therapy in cancer. Cancer Chemother Pharmacol 2015 0.75
22 Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis 2016 0.75
23 Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. Pharmgenomics Pers Med 2015 0.75
24 Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther 2016 0.75
Next 100